J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease

Johnson & Johnson disclosed new Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas. Results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting. TREMFYA delivered consistent fistula remission outcomes across difficult-to-treat groups, including patients previously treated with biologics. Safety findings matched the drug’s established profile in Crohn’s disease, supporting its positioning in a high unmet-need complication. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via (Ref. ID: 202610121605PR_NEWS_USPR_____NY69911) on October 12, 2026, and is solely responsible for the information contained therein. (C)